A Revolutionary Blood Test for Early Detection and Monitoring of Colorectal Cancer

Mediven bring you ColonAiQ®, an advanced, blood-based, non-invasive test that detects colorectal cancer through cutting-edge multi-gene methylation technology. This powerful diagnostic tool helps identify early-stage cancer and monitor patients after surgery for signs of recurrence — all from a simple blood draw.

Why Choose

ColonAiQ®?

High Sensitivity & Specificity

Backed by peer-reviewed publications, ColonAiQ® demonstrated up to 86% sensitivity across all CRC stages and 92% specificity among healthy individuals, outperforming traditional screening methods like FIT and CEA.

For Early Detection

& Ongoing Monitoring

ColonAiQ® can be used for people with positive fecal occult blood test results or symptoms such as changes in bowel habits, for cancer screening in both average- and high-risk individuals, and for post-surgery monitoring in Stage I–III colorectal cancer patients to detect any remaining disease and assess the risk of recurrence.

Trusted by Physicians

Recommended by healthcare professionals for both initial screening and ongoing surveillance. ColonAiQ® can detect circulating tumor DNA (ctDNA) methylation changes months before imaging tests reveal recurrence.

How ColonAiQ® Works?

All tests are processed using validated instruments and protocols, ensuring reliable, high-quality results.

Colonia® Aim To:

“Make early detection easier than ever — no fasting, no preparation, no discomfort.”

Powered by Science. Proven by Research.

ColonAiQ® is supported by multiple high-impact clinical studies published in:

  • Gastroenterology (2021)
  • JAMA Oncology (2023)
  • BMC Medicine (2024)

These studies confirm ColonAiQ®’s role in:

  • Early cancer detection
  • Recurrence prediction
  • Risk stratification
  • Improving colonoscopy compliance